NEW YORK & LONDON & PARIS – (BUSINESS WIRE) – April 22, 2021 –

Regulatory news:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company, through its subsidiary, has entered into a material transfer agreement and option (“Agreement”) with Yale University (“Yale”) to evaluate a group of new preclinical immunomodulators. The new immunomodulators have the potential to target autoimmune and oncological diseases including, but not limited to rheumatoid arthritis, lupus and sclerosis, as well as a variety of cancers, all subject to development and disease. additional preclinical testing. Aptorum has also obtained an exclusive option to license the new immunomodulators and its affiliated intellectual property rights, including its patent rights and know-how, on the basis of license conditions in accordance with a binding conditions sheet incorporated in the Agreement.

As part of this arrangement, Aptorum will be responsible for evaluating new immunomodulators originally developed by Yale for lupus, arthritis, inflammatory bowel disease, neurodegenerative disease or other oncological indications. After exercising its licensing option, Aptorum will undertake to develop and commercialize one or more of these novel immunomodulators, as supported by Yale.

Mr. Ian Huen, CEO of Aptorum Group, said: “Aptorum is delighted to partner with Yale to validate and develop its new class of immunomodulators. Aptorum believes that these immunomodulators have the potential to advance the discovery of first-rate drugs and the development of such drugs for potential autoimmune and oncological diseases in particular. For example, it has been widely reported that COVID-19 infections often trigger a cytokine storm in patients leading to unwanted and often fatal self-synthetic reactions 1 and we will also explore the potential applications of immunomodulators for treatment. of these cytokine storms. Through this initiative, we look forward to strategically expanding our development footprint in the treatment of these diseases, which have other potential applications such as oncology and infectious diseases which are already at the heart of our business priorities.

About the Aptorum group

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic actives to treat diseases with unmet medical needs, in particular infectious diseases and cancers (including orphan oncological indications). Aptorum’s pipeline is also enriched by the establishment of drug discovery platforms that enable the discovery of new therapeutic assets through programs such as the systematic screening of existing approved drug molecules and a research platform. based on the microbiome for the treatment of metabolic diseases. Aptorum also has projects focused on microbiome research and the commercialization of a natural supplement for use in postmenopausal women with associated symptoms.

For more information on Aptorum Group, please visit www.aptorumgroup.com.

About the Yale Cooperative Research Office, Yale University

Since its creation in 1982, the Yale Office of Cooperative Research (OCR) has built up a large portfolio of inventions and patents and has become an engine of regional economic development. Its mission is to help translate Yale lab research into products and services that benefit society. OCR is recognized as a driving force to catalyze economic growth by identifying, advising and supporting early stage technologies and guiding the transition to strong businesses. More information is available at https://ocr.yale.edu/

Disclaimer and forward-looking statements

This press release does not constitute an offer to sell or a solicitation of offers to buy shares of Aptorum Group.

This press release contains statements about Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. To this end, all statements contained in this document that are not statements of historical fact may be considered forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may”, “should”, “expects”, “anticipates”, “anticipates”, “could”, “intends”, “targets” “,” Projects, “” Consider “,” believe “,” estimate “,” predict “,” potential “or” continue “, or the negative of these or other similar terms. The Aptorum Group has based these forward-looking statements, which include statements regarding the expected timeframes for submission and testing of candidates, in large part on its current expectations and projections regarding future events and trends that it believes could affect its business. activities, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risks associated with its stated management. and organizational changes, continuous service and the availability of key personnel. , its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, as well as its expectations relating to and the stability of its supply chain the risks described in more detail in the Aptorum Group Form 20-F and other filings the Aptorum Group may make with the SEC in the future, as well as in the prospectus which received visa from the Autorité des marchés financiers n ° 20-352 on July 16, 2020.

Accordingly, the projections included in these forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of regulation (EU) n ° 2017/1129 of June 14, 2017 amended by delegated regulations (EU) n ° 2019/980 of March 14, 2019 and n ° 2019/979 of March 14 2019.

This press release is provided “as is” without any representation or warranty of any kind.

1 Inflamm Regen. 2020; 40:37.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210422005054/en/

CONTACT: Aptorum Group Limited

Investor Relations Department:

[email protected]

+44 20 80929299

Redchip – Financial communications United States

Investor Relations

Dave gentry

[email protected]

+1 407 491 4498

Actifin – Financial communication Europe

Investor Relations

Ghislaine Gasparetto

[email protected]

+33 1 56 88 11 22

KEYWORD: CHINA UNITED STATES FRANCE UNITED KINGDOM NORTH AMERICA ASIA PACIFIC EUROPE NEW YORK

INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS BIOTECHNOLOGY UNIVERSITY OF PHARMACEUTICAL HEALTH SCIENCE EDUCATION ONCOLOGY

SOURCE: Aptorum Group Limited

Copyright Business Wire 2021.

PUB: 04/22/2021 7:00 a.m. / DISC: 04/22/2021 7:01 a.m.

http://www.businesswire.com/news/home/20210422005054/en